These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 16211062)
1. Antibodies in the breakdown lane. Blumberg RS; Lencer WI Nat Biotechnol; 2005 Oct; 23(10):1232-4. PubMed ID: 16211062 [No Abstract] [Full Text] [Related]
2. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Vaccaro C; Zhou J; Ober RJ; Ward ES Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811 [TBL] [Abstract][Full Text] [Related]
3. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. Wang Y; Tian Z; Thirumalai D; Zhang X J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896 [TBL] [Abstract][Full Text] [Related]
5. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551 [TBL] [Abstract][Full Text] [Related]
6. Engineered clearing agents for the selective depletion of antigen-specific antibodies. Devanaboyina SC; Khare P; Challa DK; Ober RJ; Ward ES Nat Commun; 2017 May; 8():15314. PubMed ID: 28561044 [TBL] [Abstract][Full Text] [Related]
7. Structure and function of human and murine receptors for IgG. Unkeless JC; Scigliano E; Freedman VH Annu Rev Immunol; 1988; 6():251-81. PubMed ID: 2968084 [No Abstract] [Full Text] [Related]
8. Fc-dependent mechanisms of action: roles of FcγR and FcRn. Kuijpers T Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):89-91. PubMed ID: 25546775 [No Abstract] [Full Text] [Related]
9. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Sockolosky JT; Szoka FC Adv Drug Deliv Rev; 2015 Aug; 91():109-24. PubMed ID: 25703189 [TBL] [Abstract][Full Text] [Related]
10. Engineering therapeutic monoclonal antibodies. Liu XY; Pop LM; Vitetta ES Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992 [TBL] [Abstract][Full Text] [Related]
11. Editorial: Antibody Fc Engineering: Towards Better Therapeutics. Lei C; Gong R; Ying T Front Immunol; 2018; 9():2450. PubMed ID: 30405636 [No Abstract] [Full Text] [Related]
12. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808 [TBL] [Abstract][Full Text] [Related]
14. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution. Pollastrini J; Dillon TM; Bondarenko P; Chou RY Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563 [TBL] [Abstract][Full Text] [Related]
15. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Vaccaro C; Bawdon R; Wanjie S; Ober RJ; Ward ES Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18709-14. PubMed ID: 17116867 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics (PK) of mAbs]. Paintaud G Med Sci (Paris); 2009 Dec; 25(12):1057-62. PubMed ID: 20035679 [TBL] [Abstract][Full Text] [Related]
18. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Oksenhendler E Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):92-3. PubMed ID: 25546776 [No Abstract] [Full Text] [Related]